We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genedata Releases Screen-to-Lead Data Analysis and Management Platform Genedata Screener® 5.5
Product News

Genedata Releases Screen-to-Lead Data Analysis and Management Platform Genedata Screener® 5.5

Genedata Releases Screen-to-Lead Data Analysis and Management Platform Genedata Screener® 5.5
Product News

Genedata Releases Screen-to-Lead Data Analysis and Management Platform Genedata Screener® 5.5


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Genedata Releases Screen-to-Lead Data Analysis and Management Platform Genedata Screener® 5.5"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genedata has announced the release of Genedata Screener 5.5, its new enterprise solution for high throughput and high content screening analysis.

The Screener platform, currently in use at several large pharmaceutical and biotech companies, combines enterprise-wide assay data management with high-performance processing workflows and flexible analysis tools.

Screener can analyze, integrate and manage all assay data, independent of instrumentation, technology, volume or location. The findings are then combined with chemical, pharmacological and in vivo data to support scientists in the tasks of compound prioritization and identification of quality lead structures with the highest confidence.

Screener 5.5 features easy integration of pharmacological fit models and advanced functionality for analyzing experiments with multiple readouts. Users will benefit from the ability to integrate new fit models that are relevant for their particular workflows, such as the Morrison equation for Ki fitting, or new proprietary and public fit algorithms.

In addition, the open and scalable architecture extends Screener’s applicability as enterprise screening analysis platform, from uHTS centers to therapeutic areas, and provides access to a wide range of information in corporate research and drug discovery systems.

Advertisement